Compare Divis Laboratories with Novartis - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

DIVIS LABORATORIES vs NOVARTIS - Comparison Results

DIVIS LABORATORIES     Change

Established in the year 1990, Divi's Laboratories has been focusing on CRAMS and is an established player in the custom chemical synthesis (CCS) and API/Intermediate segment. Around 50% of Divi's revenues are derived from custom manufacturing for glo... More

NOVARTIS 
   Change

Novartis is a 76% subsidiary of Novartis AG - Switzerland and has a countrywide presence in the healthcare business. While pharmaceuticals contributes 70% to total revenues (FY10), generics (6%), consumer healthcare i.e. OTC (14%) and animal health (... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    DIVIS LABORATORIES NOVARTIS DIVIS LABORATORIES/
NOVARTIS
 
P/E (TTM) x 53.6 2,179.5 2.5% View Chart
P/BV x 14.3 28.9 49.6% View Chart
Dividend Yield % 0.4 1.5 27.9%  

Financials

 DIVIS LABORATORIES   NOVARTIS
EQUITY SHARE DATA
    DIVIS LABORATORIES
Mar-19
NOVARTIS
Mar-19
DIVIS LABORATORIES/
NOVARTIS
5-Yr Chart
Click to enlarge
High Rs1,639980 167.3%   
Low Rs1,115600 185.8%   
Sales per share (Unadj.) Rs186.3198.7 93.8%  
Earnings per share (Unadj.) Rs51.021.0 243.0%  
Cash flow per share (Unadj.) Rs57.322.3 257.5%  
Dividends per share (Unadj.) Rs16.0010.00 160.0%  
Dividend yield (eoy) %1.21.3 91.8%  
Book value per share (Unadj.) Rs261.8307.5 85.1%  
Shares outstanding (eoy) m265.4724.69 1,075.2%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x7.44.0 185.9%   
Avg P/E ratio x27.037.7 71.7%  
P/CF ratio (eoy) x24.035.5 67.7%  
Price / Book Value ratio x5.32.6 204.7%  
Dividend payout %31.447.7 65.8%   
Avg Mkt Cap Rs m365,59219,508 1,874.1%   
No. of employees `00011.80.6 2,039.1%   
Total wages/salary Rs m5,4231,171 463.0%   
Avg. sales/employee Rs Th4,175.18,445.4 49.4%   
Avg. wages/employee Rs Th457.72,015.7 22.7%   
Avg. net profit/employee Rs Th1,141.8891.0 128.1%   
INCOME DATA
Net Sales Rs m49,4634,907 1,008.0%  
Other income Rs m1,556783 198.9%   
Total revenues Rs m51,0195,689 896.7%   
Gross profit Rs m18,718123 15,243.0%  
Depreciation Rs m1,68932 5,311.3%   
Interest Rs m3516 220.1%   
Profit before tax Rs m18,551858 2,162.8%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m5,023340 1,477.4%   
Profit after tax Rs m13,527518 2,613.0%  
Gross profit margin %37.82.5 1,512.1%  
Effective tax rate %27.139.6 68.3%   
Net profit margin %27.310.6 259.2%  
BALANCE SHEET DATA
Current assets Rs m46,5018,055 577.3%   
Current liabilities Rs m8,4681,850 457.7%   
Net working cap to sales %76.9126.4 60.8%  
Current ratio x5.54.4 126.1%  
Inventory Days Days13145 290.6%  
Debtors Days Days8634 253.1%  
Net fixed assets Rs m25,797150 17,220.8%   
Share capital Rs m531123 430.2%   
"Free" reserves Rs m68,9627,469 923.4%   
Net worth Rs m69,4937,592 915.4%   
Long term debt Rs m00-   
Total assets Rs m80,3839,824 818.2%  
Interest coverage x531.054.9 966.5%   
Debt to equity ratio x00-  
Sales to assets ratio x0.60.5 123.2%   
Return on assets %16.95.4 310.6%  
Return on equity %19.56.8 285.5%  
Return on capital %26.711.5 232.4%  
Exports to sales %00-   
Imports to sales %24.60-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs m12,187NA-   
Fx inflow Rs m41,23858 71,593.1%   
Fx outflow Rs m12,4051,326 935.3%   
Net fx Rs m28,833-1,269 -2,272.6%   
CASH FLOW
From Operations Rs m9,543-1,943 -491.2%  
From Investments Rs m-6,8542,742 -249.9%  
From Financial Activity Rs m-2,459-298 824.7%  
Net Cashflow Rs m230501 45.8%  

Share Holding

Indian Promoters % 52.0 0.0 -  
Foreign collaborators % 0.0 75.0 -  
Indian inst/Mut Fund % 11.8 2.0 590.0%  
FIIs % 19.0 1.6 1,187.5%  
ADR/GDR % 0.0 0.0 -  
Free float % 17.2 21.5 80.0%  
Shareholders   31,796 41,647 76.3%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare DIVIS LABORATORIES With:   ORCHID PHARMA  WYETH  TORRENT PHARMA  SUVEN LIFE SCIENCES  DR. REDDYS LAB  

Compare DIVIS LABORATORIES With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Trades Marginally Lower, Dow Futures Up by 18 Points(12:30 pm)

Share markets in India are presently trading marginally lower. The BSE Sensex is trading down by 17 points, flat at 48,064 levels.

Related Views on News

DIVIS LABORATORIES Announces Quarterly Results (3QFY21); Net Profit Up 27.9% (Quarterly Result Update)

Feb 10, 2021 | Updated on Feb 10, 2021

For the quarter ended December 2020, DIVIS LABORATORIES has posted a net profit of Rs 5 bn (up 27.9% YoY). Sales on the other hand came in at Rs 17 bn (up 19.1% YoY). Read on for a complete analysis of DIVIS LABORATORIES's quarterly results.

DIVIS LABORATORIES Announces Quarterly Results (1QFY21); Net Profit Up 84.1% (Quarterly Result Update)

Aug 10, 2020 | Updated on Aug 10, 2020

For the quarter ended June 2020, DIVIS LABORATORIES has posted a net profit of Rs 5 bn (up 84.1% YoY). Sales on the other hand came in at Rs 17 bn (up 50.0% YoY). Read on for a complete analysis of DIVIS LABORATORIES's quarterly results.

DIVIS LABORATORIES Announces Quarterly Results (4QFY20); Net Profit Up 35.4% (Quarterly Result Update)

Jun 8, 2020 | Updated on Jun 8, 2020

For the quarter ended March 2020, DIVIS LABORATORIES has posted a net profit of Rs 4 bn (up 35.4% YoY). Sales on the other hand came in at Rs 14 bn (up 9.5% YoY). Read on for a complete analysis of DIVIS LABORATORIES's quarterly results.

NOVARTIS Announces Quarterly Results (3QFY20); Net Profit Down 39.9% (Quarterly Result Update)

Feb 17, 2020 | Updated on Feb 17, 2020

For the quarter ended December 2019, NOVARTIS has posted a net profit of Rs 77 m (down 39.9% YoY). Sales on the other hand came in at Rs 1 bn (down 13.4% YoY). Read on for a complete analysis of NOVARTIS's quarterly results.

DIVIS LABORATORIES Announces Quarterly Results (3QFY20); Net Profit Down 4.9% (Quarterly Result Update)

Feb 6, 2020 | Updated on Feb 6, 2020

For the quarter ended December 2019, DIVIS LABORATORIES has posted a net profit of Rs 4 bn (down 4.9% YoY). Sales on the other hand came in at Rs 14 bn (up 3.5% YoY). Read on for a complete analysis of DIVIS LABORATORIES's quarterly results.

More Views on News

Most Popular

India: Recovery Stalled by Vaccine Games?(The Honest Truth)

Apr 13, 2021

Ajit Dayal on how India's vaccine strategy will impact the markets.

Top 3 Nifty ETFs to Buy Now(Fast Profits Daily)

Apr 20, 2021

In this video I tell you the three Nifty ETFs I think are the best.

A Stock with 700% Return Potential Comes with Additional Payoffs(Profit Hunter)

Apr 15, 2021

Narayana Murthy was one of the first unicorn founders to get the backing of this entity...

11x Bankruptcy to Bluechip Stock: A Rare India Revival Story(Profit Hunter)

Apr 16, 2021

There is no stopping this 11-bagger stock from significant upside.

Why Did the Market Crash on Monday?(Fast Profits Daily)

Apr 13, 2021

In this video, I'll you what I think is the real reason behind yesterday's market crash.

More

India's #1 Trader
Reveals His Secrets

Secret To Increasing Your Trading Profits Today
Get this Special Report,
The Secret to Increasing Your Trading Profits Today, Now!
We will never sell or rent your email id.
Please read our Terms

DIVIS LABORATORIES SHARE PRICE


Apr 23, 2021 12:53 PM

TRACK DIVIS LABORATORIES

  • Track your investment in DIVIS LABORATORIES with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON DIVIS LABORATORIES

DIVIS LABORATORIES - NEULAND LABS COMPARISON

COMPARE DIVIS LABORATORIES WITH

MARKET STATS